Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Crinetics Pharmaceuticals Operating Margin % Related Terms
Crinetics Pharmaceuticals Operating Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRNX vs ACAD, VKTX, EWTX: Operating Margin % Comparison
For the Biotechnology subindustry, Crinetics Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crinetics Pharmaceuticals Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Crinetics Pharmaceuticals's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Crinetics Pharmaceuticals's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Crinetics Pharmaceuticals's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Margin % of -1,307.79% mean?
Crinetics Pharmaceuticals (CRNX) has a Operating Margin % of -1,307.79% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Crinetics Pharmaceuticals and its competitors. According to the industry distribution chart, Crinetics Pharmaceuticals ranks #817 out of 943 companies in the Biotechnology industry, placing it in the top 86.6%.
Is Crinetics Pharmaceuticals' Operating Margin % too high?
Crinetics Pharmaceuticals' current Operating Margin % is -1,307.79%. Based on the distribution chart, Crinetics Pharmaceuticals ranks #817 out of 943 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Crinetics Pharmaceuticals has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Crinetics Pharmaceuticals' Operating Margin % compare to ACAD and VKTX?
According to the Biotechnology industry distribution chart, Crinetics Pharmaceuticals ranks #817 out of 943 companies for Operating Margin %. This places Crinetics Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Crinetics Pharmaceuticals and its competitors. Crinetics Pharmaceuticals's current Operating Margin % is -1,307.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crinetics Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Crinetics Pharmaceuticals (CRNX) is currently considered Possible Value Trap. The stock's GF Value™ is $678.51, compared to a current price of $36.64 — trading 94.6% below its estimated fair value. The current Operating Margin % is -1,307.79%. Crinetics Pharmaceuticals' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Crinetics Pharmaceuticals (CRNX), the current Operating Margin % is -1,307.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Crinetics Pharmaceuticals (CRNX) Overvalued in 2026?
Based on GuruFocus' analysis, Crinetics Pharmaceuticals stock appears to be undervalued.
The current stock price of $36.64 is trading 94.6% below its estimated GF Value™ of $678.51.
GuruFocus considers Crinetics Pharmaceuticals to be Possible Value Trap.
Key valuation signals for CRNX:
Operating Margin %: -1,307.79%
GF Value™: $678.51 vs. price of $36.64 (94.6% below fair value)
No single metric tells the full story. See the CRNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
47GF Score
Get the complete analysis for CRNX
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRNX has been successfully added to your 
